Orient Gene, a large Chinese manufacturer of IVD products who had a hit-run success in Asia, US and Europe during the pandemic manufacturing and supplying covid tests at scale now wanted to expand it’s permanent footprint in Europe. The result; the acquisition of a state of the art factory in Scotland and the formation of Accubio. With an expansive product portfolio, the question turned on where to start first.
The Process
Capitalising on the success of the last few years the business now needed a new focus and whilst Orient Gene was known for being a manufacturer of covid kits, it was little known in Europe for anything else. Furthermore the incorporation of a new wholly owned entity, Accubio, prior to our appointment meant that we were dealing with a new business, unknown to anyone – in essence starting from afresh.
The Plan
After strategising with the management team it was decided that primary focus was to centre around the drugs of abuse market which is a stable consistent market being legislated by statute and with relatively few vital players in the space.Focusing on the vital few players and labs, the team set a goal of sourcing founding strategic partners who would be best place to support long term sustainable growth and market integrity.
The Result
Accubio has developed its place in the drugs of abuse sector within the UK and in a commodity driven market set itself apart by working with key stakeholders to differentiate its offering and add value to its customers at every turn. Key take aways are listen to what your customers need are and make their life easier at every turn.